Ragazzoni E, Sacco A, Cusinato S, Agliata S, Schweiger K, Cavagnino A, Zanetta M, Cardillo V, Corrà U
Servizio di Nefrologia e Dialisi, Ospedale, Borgomanero, Novara.
Minerva Urol Nefrol. 1998 Jun;50(2):133-8.
The congestive heart failure (IV cl. NYHA) refractory to medical therapy, can be treated with ultrafiltrative method such as extracorporeal ultrafiltration (UF), intermittent veno-venosus hemofiltration, intermittent peritoneal dialysis (IPD) or chronic ambulatory peritoneal dialysis (CAPD).
Sixty-one patients suffering from SCC have been managed by combining medical therapy with ultrafiltrative treatment.
28% (17 patients) died within a week from ultrafiltrative therapy beginning. 39% (24 patients) took up to respond to medical therapy (responders). 33% (20 patients) didn't give a proper response to pharmacological therapy (non responders), therefore a ultrafiltration program with chronic ambulatory peritoneal dialysis (CAPD) has been undertaken. Among ultrafiltrative methods applied to patients, IVVH is the most effective. Clinical parameters analysis, relevant to dehydration acute phase, points out: an evident loss of corporeal weight between dehydration pre-post phases in all 3 groups, with statistically significant results; a SAP values reduction between the beginning and the end of treatment in all 3 groups; a PAD values reduction in the group of deceased and non responders. This value remains stable in responders group. Non responders patients, inserted in a ultrafiltration program with CAPD present the following survival rate: 55%: 6 months; 35%: 1 years; 15%: 4 years. These patients maintain a good self-management in 50%, sufficient in 35% and totally partner-dependent in 15%.
Ultrafiltration method together with pharmacological therapy allows a resetting of neuro-endocrine and electrolytic system in refractory congestive heart failure patients and a recovery of a pharmacological response. Without such a response a cardio-circulatory balance can be maintained through a CAPD method.
药物治疗难治的充血性心力衰竭(纽约心脏协会IV级),可用超滤方法治疗,如体外超滤(UF)、间歇性静脉-静脉血液滤过、间歇性腹膜透析(IPD)或持续性非卧床腹膜透析(CAPD)。
61例患有严重慢性心力衰竭(SCC)的患者采用药物治疗与超滤治疗相结合的方法进行处理。
28%(17例患者)在超滤治疗开始后一周内死亡。39%(24例患者)对药物治疗有反应(有反应者)。33%(20例患者)对药物治疗无适当反应(无反应者),因此采用了持续性非卧床腹膜透析(CAPD)的超滤方案。在应用于患者的超滤方法中,静脉-静脉血液滤过(IVVH)最有效。与脱水急性期相关的临床参数分析指出:所有3组在脱水前后阶段体重均有明显减轻,结果具有统计学意义;所有3组治疗开始时与结束时收缩压(SAP)值均降低;死亡组和无反应者组舒张压(PAD)值降低。该值在有反应者组中保持稳定。采用CAPD超滤方案的无反应者患者的生存率如下:6个月时为55%;1年时为35%;4年时为15%。这些患者50%能保持良好的自我管理能力,35%足够自理,15%完全依赖他人。
超滤方法与药物治疗一起可使难治性充血性心力衰竭患者的神经内分泌和电解质系统恢复正常,并恢复药物反应。若无此反应,可通过CAPD方法维持心血管平衡。